Organovo Appoints Norman Staskey as CFO to Drive Future Growth
Portfolio - People | Jan 06, 2025 | EIN
Organovo Holdings, Inc., a clinical-stage biotechnology company, has appointed Norman Staskey as Chief Financial Officer. Staskey brings over 25 years of experience in capital markets and mergers and acquisition (M&A) transactions to the role, including significant experience in the biotechnology sector. Previously, Staskey worked with Danforth Advisors, managing financial services for clients like Azitra, Inc. His expertise is expected to enhance Organovo's strategic initiatives as it continues to develop its lead drug, FXR314, targeting inflammatory bowel disease and liver diseases. FXR314 has shown promising results in recent Phase 2 studies and preclinical models. Organovo’s proprietary 3D tissue technology plays a critical role in these developments. Alongside these advancements, Organovo remains vigilant in managing potential risks linked to forward-looking business statements.
Sectors
- Biotechnology
- Pharmaceutical
- Financial Services
Geography
- United States – Organovo is based in San Diego, California, and the article discusses their activities mainly within the United States.
Industry
- Biotechnology – The article discusses Organovo, which is a biotechnology company developing treatments for inflammatory bowel disease and liver diseases using advanced 3D tissue technologies.
- Pharmaceutical – Organovo is involved in the development of drug candidates, particularly FXR314, which addresses inflammatory and metabolic diseases.
- Financial Services – Norman Staskey’s background in capital markets and M&A transactions is relevant as he assumes the role of CFO of Organovo.
Financials
- – The article does not specify any precise financial amounts regarding the appointment of the CFO or valuation of FXR314.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Organovo Holdings, Inc. | Target Company | Company | A clinical-stage biotechnology firm pioneering the development of novel treatments using 3D biological models. |
| Norman Staskey | New CFO | Person | Recently appointed Chief Financial Officer of Organovo, with extensive experience in capital markets and biotechnology M&A. |
| Danforth Advisors | Previous Company | Company | A financial advisory firm where Norman Staskey served clients as CFO. |
| EY (Ernst & Young) | Previous Firm | Company | A multinational professional services firm where Norman Staskey was a Managing Director in the national transactions practice. |